determine whether neoplastic deposits represent
metastases or new primary lung cancer
Mutations of tumor suppressor genes and/or oncogenes are frequently identified in human cancers. These mutations often appear before detectable morphological changes. Identification of the mutational profile may be a useful indicator to:
Specimens derived from solid tumors including colorectal, lung, breast, gynecologic, and liver are appropriate for this analysis.
Microdissection to obtain minute representative areas of cellular atypia followed by polymerase chain
reaction (PCR) / Fragment based analysis for loss of heterozygosity (LOH) using a panel of microsatellite markers in proximity to 16 tumor suppressor genes including P16, PTEN, TP53, VHL, DPC4, and OGG1.
Analysis of oncogenes and additional markers of tumor suppressor genes may be added to the panel depending on the type of organ, tissue, or histopathology.
Testing can be initiated only upon receipt of a signed, completed requisition for RespriDx. All available imaging or clinical data, such as cytology or histopathology reports, should be submitted. Clinical data will be included in the integrated report. Contact Client Services at 1-800-495-9885 for details.
Less than 18 business days after receipt of specimen or fluid and a signed, completed test requisition.
Histopathology slides – Formalin fixed, paraffin embedded (FFPE) tissues:
Mutational analysis is not intended for: